Technology stocks still were adding to their day-long advance, with shares of technology companies in the S&P 500 gaining 0.7% Thursday. In company news, Tessera Technologies (NASDAQ:TSRA) is up more than 8% this afternoon after the maker of miniaturization technologies said it will receive $196 million after reaching a settlement with Powertech Technology Co. Ltd….
Financial shares were lower in pre-market session Thursday ahead of durable goods orders data, which is expected to show a slowdown. In financial stocks news, Toronto-Dominion (NYSE:TD, TD.TO) was up about 4% pre-market after it reported adjusted Q1 earnings per share were C$1.06, compared with C$1.00 a year prior. The Street expected earnings of C$1.05…
Valeant Pharmaceuticals International (NYSE:VRX) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in VRX indicates that the price change in the extended hours is…
Huntington Ingalls Industries (NYSE:HII) reported Q4 earnings that were well ahead of analysts’ estimates. The ship- and submarine builder said its adjusted diluted earnings rose nearly 28% to $1.66, exceeding the $1.22 average estimate from analysts polled by Capital IQ, if comparable. On a non-adjusted basis, diluted net earnings rose to $91 million from $50…
Tesla (NASDAQ:TSLA) edges higher in after-hours trading, having hit another record high, at $265, in Wednesday’s regular trading session, after it files to sell $1.6 billion in convertible debt. Of the total offering, the luxury electric car maker will offer $800 million aggregate principal amount of convertible senior notes due 2019 and $800 million aggregate…
Aegerion Pharmaceuticals (NASDAQ:AEGR) is lower after it reported a Q4 loss that was smaller than analysts had expected and set a FY14 sales guidance that straddled estimates. Shares are down 11.48% at $58.73 with a 52-week range of $28.33 – $101.00. In the quarter, the biopharmaceutical company had a non-GAAP loss of $0.14 per share,…
